The paradigm for the treatment of chronic hepatitis C (CHC) has been changed due to the development of direct acting antivirals (DAAs) of hepatitis C virus (HCV). The high sustained virologic response rate and ease of administration makes the DAAs approach ideal to contribute to the complete eradication of HCV. Currently, treatment options for individual patients vary depending on the genotype or subtype of HCV, presence or absence of liver cirrhosis, previous experience of antiviral treatment or resistance associated substitutions. Because of drug avalilability, cost-effectiveness, preference, compliance and greater possibility of desirable effects and presumed patient-important outcomes may vary between countries, treatment options for individual patients are different. The review focuses on the comparing the current treatment options for CHC in other continents with the 2017 Korea Association for the Study of the Liver guidelines.
Citations
Citations to this article as recorded by
Consideration of ledipasvir/sofosbuvir as an alternative to glecaprevir/pibrentasvir based upon on-treatment FIB-4 changes and sustained virologic response at 12 weeks in hepatitis C genotype 1 and 2 infections: A propensity score-matched study Hyun Joon Park, Hoyoung Wang, Joonho Jeong, Kwang Il Seo, Jung Woo Shin, Neung Hwa Park Medicine.2025; 104(47): e46079. CrossRef
Evaluating long-term outcomes of direct-acting antiviral therapy in chronic hepatitis C: A retrospective study Bo Ram Sung, Sang Goon Shim, Kwang Min Kim, Jung Won Lee, Jun Young Kim, Bo Kyeong Lee, Cheon Hoo Jun, Byung Soo Kwan Medicine.2025; 104(50): e46449. CrossRef
Chronic Hepatitis C Infection Treated with Direct-Acting Antiviral Agents and Occurrence/Recurrence of Hepatocellular Carcinoma: Does It Still Matter? Carlo Smirne, Maria Grazia Crobu, Irene Landi, Nicole Vercellino, Daria Apostolo, David James Pinato, Federica Vincenzi, Rosalba Minisini, Stelvio Tonello, Davide D’Onghia, Antonio Ottobrelli, Silvia Martini, Christian Bracco, Luigi Maria Fenoglio, Mauro Viruses.2024; 16(12): 1899. CrossRef
Characterization of Incident Hepatitis C Virus Infection among People Living with HIV in a HIV Clinic in Korea BumSik Chin, Yeonjae Kim, Gayeon Kim, Jaehyun Jeon, Min-Kyung Kim, Jae Yoon Jeong, Hyeokchoon Kwon, Seongwoo Nam Infection & Chemotherapy.2024; 56(4): 544. CrossRef
Efficacy and safety of glecaprevir/pibrentasvir treatment in Koreans with chronic hepatitis C: A retrospective study Byung Soo Kwan, Sung Min Kong, Sang Goon Shim, Kwang Min Kim, Gil Jong Yu, Jae Jin Lee, Jin Dong Kim Arab Journal of Gastroenterology.2023; 24(2): 104. CrossRef
Real-life experience of ledipasvir and sofosbuvir for HCV infected Korean patients: a multicenter cohort study Soon Kyu Lee, Sung Won Lee, Hae Lim Lee, Hee Yeon Kim, Chang Wook Kim, Do Seon Song, U Im Chang, Jin Mo Yang, Sun Hong Yoo, Jung Hyun Kwon, Soon Woo Nam, Seok-Hwan Kim, Myeong Jun Song, Jaejun Lee, Hyun Yang, Si Hyun Bae, Ji Won Han, Heechul Nam, Pil Soo The Korean Journal of Internal Medicine.2022; 37(6): 1167. CrossRef
Safety and effectiveness of direct-acting antivirals in patients with chronic hepatitis C and chronic kidney disease Ji Eun Ryu, Myeong Jun Song, Seok-Hwan Kim, Jung Hyun Kwon, Sun Hong Yoo, Soon Woo Nam, Hee Chul Nam, Hee Yeon Kim, Chang Wook Kim, Hyun Yang, Si Hyun Bae, Do Seon Song, U Im Chang, Jin Mo Yang, Sung Won Lee, Hae Lim Lee, Soon Kyu Lee, Pil Soo Sung, Jeong The Korean Journal of Internal Medicine.2022; 37(5): 958. CrossRef
Real-world Effectiveness and Safety of Direct-acting Antiviral Agents in Patients with Chronic Hepatitis C Genotype 2 Infection: Korean Multicenter Study Yeo Wool Kang, Yang Hyun Baek, Sung Wook Lee, Sung-Jae Park, Jun Sik Yoon, Ki Tae Yoon, Youngmi Hong, Nae-Yun Heo, Kwang Il Seo, Sang Soo Lee, Hyun Chin Cho, Jung Woo Shin Journal of Korean Medical Science.2021;[Epub] CrossRef
Efficacy and Safety of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase II/III Trials Jeong Heo, Yoon Jun Kim, Jin-Woo Lee, Ji Hoon Kim, Young-Suk Lim, Kwang-Hyub Han, Sook-Hyang Jeong, Mong Cho, Ki Tae Yoon, Si Hyun Bae, Eric D. Crown, Linda M. Fredrick, Negar Niki Alami, Armen Asatryan, Do Hyun Kim, Seung Woon Paik, Youn-Jae Lee Gut and Liver.2021; 15(6): 895. CrossRef
Interferon Response in Hepatitis C Virus-Infected Hepatocytes: Issues to Consider in the Era of Direct-Acting Antivirals Pil Soo Sung, Eui-Cheol Shin International Journal of Molecular Sciences.2020; 21(7): 2583. CrossRef
Full-dose sofosbuvir plus low-dose ribavirin for hepatitis C virus genotype 2-infected patients on hemodialysis Hee Yeon Seo, Myeong-Sook Seo, Sun-Young Yoon, Jong Wook Choi, Soon Young Ko The Korean Journal of Internal Medicine.2020; 35(3): 559. CrossRef
Hepatocellular Carcinoma Risk According to Regimens for Eradication of Hepatitis C Virus; Interferon or Direct Acting Antivirals Hye Won Lee, Dai Hoon Han, Hye Jung Shin, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim Cancers.2020; 12(11): 3414. CrossRef
Comparison of the Clinical Characteristics and Outcomes between Leprosy-Affected Persons in Sorokdo and the General Population Affected by Chronic Hepatitis C in Korea Young-Hwan Ahn, Hyungcheol Park, Myeon Jae Lee, Dong Hyun Kim, Sung Bum Cho, Eunae Cho, Chung Hwan Jun, Sung Kyu Choi Gut and Liver.2019; 13(5): 549. CrossRef
The remaining challenges of HCV treatment in the direct‐acting antivirals era Beom Kyung Kim, Sang Hoon Ahn Journal of Gastroenterology and Hepatology.2019; 34(11): 1891. CrossRef
An integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infection Youn Jae Lee, Jeong Heo, Do Young Kim, Woo Jin Chung, Won Young Tak, Yoon Jun Kim, Seung Woon Paik, Eungeol Sim, Susila Kulasingam, Rohit Talwani, Barbara Haber, Peggy Hwang Clinical and Molecular Hepatology.2019; 25(4): 400. CrossRef
Sofosbuvir plus ribavirin for the treatment of hepatitis C virus genotype 2 in Korea: What's the optimal dosage of ribavirin in real‐world setting? Jae Hyun Yoon, Chung Hwan Jun, Ji Ho Seo, Hyun A Cho, Sung Bum Cho, Sung Kyu Choi, Ju Yeon Cho, Man Woo Kim, Sung Wook Lim Journal of Digestive Diseases.2019; 20(1): 31. CrossRef
First
Prev
